MedTrace Logo

Corticoids in Severe Community-Acquired Pneumonia (CAP)

NCT00908713 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2013-03-20

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy of glucocorticoids as an adjuvant therapy in patients with severe community-acquired pneumonia (CAP) (Fine V). The hypothesis of the study is that glucocorticoids can modulate the excessive inflammatory response in patients with severe CAP without any significant side effects, showing a benefit in the percentage of non-response to the empiric antimicrobial treatment.

Conditions

  • Community-Acquired Pneumonia

Interventions

DRUG

methylprednisolone

methylprednisolone 0.5 mg/kg body weight every 12 h for 5 days

DRUG

Placebo

Sodium chloride 0.9% 10 mL every 12 h for 5 days

Sponsors & Collaborators

  • Hospital Clinic of Barcelona

    lead OTHER

Principal Investigators

  • Carlos Agusti, MD · Hospital Clinic, Barcelona,Spain.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2012-02-29
Completion
2012-03-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00908713 on ClinicalTrials.gov